Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

BACKGROUND: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooistra, Emma J., Waalders, Nicole J. B., Grondman, Inge, Janssen, Nico A. F., de Nooijer, Aline H., Netea, Mihai G., van de Veerdonk, Frank L., Ewalds, Esther, van der Hoeven, Johannes G., Kox, Matthijs, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726611/
https://www.ncbi.nlm.nih.gov/pubmed/33302991
http://dx.doi.org/10.1186/s13054-020-03364-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726611/
https://www.ncbi.nlm.nih.gov/pubmed/33302991
http://dx.doi.org/10.1186/s13054-020-03364-w

Ejemplares similares